Take a Closer Look
Our therapeutic framework integrates neuroscience with various therapeutic tools from different traditions and can be applied with different psychedelic agents for a wide variety of conditions (trans-diagnostic).
Our efficacy data represents the results of 71 people (N=71) (unless otherwise specified) who participated in EQNMT’s psychedelic-assisted therapy program to date, resulting in a 98% success rate.
We commit to updating our data continually to provide a transparent picture of client outcomes.
Our success rate was determined by calculating the mean (average) scores of the following measures, from pre-retreat to 6 months post-retreat:
Patient Health Questionnaire (PHQ9)
The data represents changes in self-reported depression. The lower the score, the less depressed the person feels.
Yale-Brown OCD Scale
The lower the score, the milder the OCD symptoms.
Hamilton Depression Scale
The lower the score, the less depressed the person feels.
World Health Organization Quality of Life Scale (WHOQoLS)
The WHOQoLS has four scales-
Phys = Physical
Psych = Psychological
Soc = Social
Env = Environmental
The higher the score, the better the quality of life.
The data portrayed below represents changes in self-reported substance use.
The graphs represent mean (average) scores of N (number)= 25 participants from pre-retreat to 6 months post-retreat.
N = 5 cocaine
N =12 cannabis
N = 18 alcohol
Below 50= Full remission
50-60= Partial remission
60-70= Mild-moderate substance use
Above 70= Clinically significant substance abuse
The initial data indicates promising, enduring outcomes for clients seeking relief from Depression, Anxiety, OCD and Substance Use by participating in EQNMT’s evidence-based psychedelic-assisted therapy programs.
The Science of Psychedelic-Assisted Therapy
Psilocybin therapy, which involves the controlled use of the psychoactive compound psilocybin found in certain mushrooms, has shown promise as an effective treatment for a range of mental health disorders. While research in this area is ongoing, several key neuroscientific mechanisms underlie its potential efficacy:
It's important to note that psilocybin therapy is still in its early stages of research, and its efficacy and safety need further investigation. Moreover, it should only be administered in a controlled, therapeutic setting under the guidance of trained professionals.
While it holds potential as a treatment option for certain mental health disorders, it is not a standalone solution and should be considered as part of a broader approach that may include psychotherapy and other interventions.
Multiple published studies showing the safety and efficacy of psychedelic-assisted therapy.
EQNMT combines the therapeutic approaches from all of these studies to overcome the limitation of each as a standalone treatment.